Concinnity Genetics

Concinnity Genetics

Biotechnology Research

Improving the safety and efficacy of gene therapies using AI

About us

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Glasgow
Type
Privately Held
Founded
2021
Specialties
Gene Control, RNA, Artificial Intelligence, Synthetic Biology, and Gene Therapy

Locations

Employees at Concinnity Genetics

Updates

Similar pages

Funding

Concinnity Genetics 1 total round

Last Round

Seed

US$ 3.8M

See more info on crunchbase